drugset / Trial / NCT00150813

Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.

NCT00150813

Phase 3 Completed 66 enrolled UCB Pharma
Non-randomizedSingle-groupOpen-labelTreatment

Summary

An open-label follow-up trial assessing the long term safety of levetiracetam as per adverse events reporting.

Timeline

Start
2005-08-10
Primary completion
2007-05-29
Completion
2007-05-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified 500 mg Oral